

Emergency Contact information:

Emergency Prescriber Contact:

Telephone number during office hours:

Telephone number after office hours:

For complete information on the side effects of pomalidomide patients should read the package leaflet and Healthcare Professionals should read the Summary of Product Characteristics.

MHRA approval date July 2024
BBBB8285

Pomalidomide

This patient is on pomalidomide.

Information for Patients:

- You MUST tell your prescriber immediately if you experience any symptoms that cause concern
- You MUST inform your prescriber immediately if you suspect you or your female partner is pregnant.

back

front

Information for Patients and Healthcare Professionals

Pomalidomide is an immunomodulator and is an expected human teratogen therefore:

- Women of childbearing potential must use at least one effective method of contraception and male patients with pregnant partners or partners of childbearing potential not using effective contraception must always use condoms (even if man has had a vasectomy)
- Women of childbearing potential must have regular pregnancy tests to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation.
- If a female patient or female partner of a male patient suspects they are pregnant they must contact their **doctor immediately**

Information for Healthcare Professionals:

Prescription details

Prescription date:	DD	MM	YYYY
Has the patient received counselling?	Yes <input type="checkbox"/>	No <input type="checkbox"/>	
Childbearing potential assessment:	WCBP / WNCBP / Male		
This patient is receiving pomalidomide for treatment of:			
<input type="checkbox"/> Multiple Myeloma			
<input type="checkbox"/> Relapsed and Refractory Multiple Myeloma			

inside left

inside right